ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer

Niu, Xiaoge; Wang, Wei; Liang, Taizhen; Li, Shasha; Yang, Chan; Xu, Xinfeng; Li, Lin*; Liu, Shuwen*南方医科大学
Cancer Science2022-1DOI: 10.1111/cas.15190
3被引9阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) is one of the commonest lethal malignancies worldwide, and often diagnosed at an advanced stage, without any curative therapy. Immune checkpoint blockers targeting the programmed death receptor 1 (PD-1) have shown impressive antitumor activity in patients with advanced-stage HCC, while the response rate is only 30%. Inducible PD-L1 overexpression may result in a lack of response to cancer immunotherapy, which is attributed to a mechanism of adaptive immune resistance. Our study investigated that the overexpression of PD-L1 promoted the invasion and migration of liver cancer cells in vitro, and the induced overexpression of PD-L1 in the tumor microenvironment could weaken the effects of anti-PD-1 immunotherapy in a BALB/c mouse model of liver cancer. CPI-203, a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor, which can potently inhibit PD-L1 expression in vitro and in vivo, combined with PD-1 antibody improved the response to immunotherapy in a liver cancer model. Cell transfection and chromatin immunoprecipitation assay manifested that BRD4 plays a key role in PD-L1 expression; CPI-203 can inhibit PD-L1 expression by inhibiting the BRD4 occupation of the PD-L1 promoter region. This study indicates a potential clinical immunotherapy method to reduce the incidence of clinical resistance to immunotherapy in patients with HCC.

学科与关键词

关键词
BRD4 inhibitorIFN-gammaimmunotherapyliver cancerPD-L1
相关
加载中…
  • PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity
    Guo, Shuang; Wang, Xinyue; Zhou, Hanxiao; Gao, Yue; Wang, Peng; Zhi, Hui; Sun, Yue; Zhang, Yakun; Gan, Jing; Xiao, Yun*; Ning, Shangwei*Biomolecules, 2022, 12(9): 1226.被引 4
  • Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors
    Hong, Chang; Dong, Han-Zhi; Li, Rui-Ning; Zhu, Hong-Bo; Li, Qi-Mei; Cui, Hao; Hu, Cheng-Yi; Huang, Chao-Yi; Peng, Jie; Liu, Li*; Zou, Xue-Jing*; Xiao, Lu-Shan*DIGESTIVE DISEASES, 2023, 41(3): 422-430.被引 3
  • Nanobubbles containing PD-L1 Ab and miR-424 mediated PD-L1 blockade, and its expression inhibition to enable and potentiate hepatocellular carcinoma immunotherapy in mice
    Liu, Yun; Xie, Qian; Ma, Yao; Lin, Chen; Li, Jinlin; Hu, Bing; Liu, Chaoqi*; Zhao, Yun*International Journal of Pharmaceutics, 2022, 629: 122352.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Science
发表日期
2022-01
卷期
第 113 卷, 第 1 期
页码
28-40
DOI
10.1111/cas.15190
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82073898]; Major scientific and technological projects of Guangdong Province [2019B020202002]

作者

  • N

    Niu, Xiaoge (第一作者)

    new · southern med univ

  • W

    Wang, Wei

    new · southern med univ

查看全部 8 位作者收起作者
  • L

    Liang, Taizhen

    new · southern med univ

  • L

    Li, Shasha

    new · southern med univ

  • Y

    Yang, Chan

    new · southern med univ

  • X

    Xu, Xinfeng

    new · southern med univ

  • L

    Li, Lin (通讯)

    new · southern med univ

  • L

    Liu, Shuwen (通讯)

    southern med univ · new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417